Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2011-03-01
2011-03-01
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C514S556000, C514S565000
Reexamination Certificate
active
07897641
ABSTRACT:
A composition is disclosed which is suitable for the prevention and/or treatment of cell and tissue abnormalities of exogenous, toxic or metabolic origin and suitable for reducing the toxic effects of cyclosporin-A and other immunosuppressive agents, which may take the form of a food supplement or of an actual medicine, containing as its active ingredients in combination or separately packaged: (a) propionyl L-carnitine or one of its pharmacologically acceptable salts, and (b) an amino acid selected from the group consisting of glycine, serine, alanine and arginine, or mixtures thereof.
REFERENCES:
patent: 4320145 (1982-03-01), Cavazza
patent: 4963587 (1990-10-01), Iwakuma et al.
patent: 5270472 (1993-12-01), Taglialatela et al.
patent: 5290538 (1994-03-01), Bertermann
patent: 5607691 (1997-03-01), Hale et al.
patent: 5763408 (1998-06-01), Nishikawa et al.
patent: 5811457 (1998-09-01), Corsi
patent: 5922766 (1999-07-01), Acosta et al.
patent: 5955424 (1999-09-01), Calvani et al.
patent: 6063820 (2000-05-01), Cavazza
patent: 6245378 (2001-06-01), Cavazza
patent: 6306392 (2001-10-01), Cavazza
patent: 6348495 (2002-02-01), Cavazza et al.
patent: 6552070 (2003-04-01), Pola
patent: 6602512 (2003-08-01), Cavazza
patent: 6641849 (2003-11-01), Cavazza
patent: 6780851 (2004-08-01), Cavazza
patent: 6861554 (2005-03-01), Buononato
patent: 0 517 125 (1992-12-01), None
patent: WO 9843499 (1998-10-01), None
patent: WO 00/28986 (2000-05-01), None
patent: WO 00/62773 (2000-10-01), None
Ferrari et al., The propionyl-L-carnitine hypothesis: an alternative approach to treating heart failure, (1997), J Card Fail-3; pp. 1-2.
Evans et al. Excretion and Metabolism of Propionyl-L-Carnitine in the Isolated Perfused Rat Kidney, vol. 281, Issue 3, 1071-1076, 1997, printed pp. 1-14 (please see p. 3 of 14, 1st line and line 11 under Materials and Methods).
Thurman et al. (Prevention of Cyclosporine—Induced Nephrotoxicity With Dietary Glycine 1 (Transplantation, 1997, vol. 63, Issue 11, pp. 1661-1667 (Immunobiology).
Betton Timothy E
Lucas & Mercanti LLP
Padmanabhan Sreeni
Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
LandOfFree
Composition for the prevention and/or treatment of the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition for the prevention and/or treatment of the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition for the prevention and/or treatment of the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2710986